Recommendations are based on a review of the literature using Medline, PubMed, Embase, Central, Web of Science searches from the beginning of 2013 up to July 2019. The following search terms were used: myeloma; plasma cell leukaemia; AND risk; prognosis; cytogenetics; FISH; PCR; molecular; imaging; response; residual disease OR [chemotherapy; autologous; autograft; HDT/ASCT; allogeneic; allograft; stem cell; bone marrow; cord blood; haploidentical; tandem transplant; bortezomib; carfilzomib; ixazomib; melphalan; thalidomide; lenalidomide; pomalidomide; cyclophosphamide; dexamethasone; prednisolone; doxorubicin; bendamustine; immunotherapy; daratumumab; PDL1 inhibitor; CAR-T; frail; elderly; renal failure; renal impairment; kidney disease; maintenance; consolidation AND survival; outcome; relapse; progression; remission; response; residual disease; mortality; morbidity; side effects; adverse events; complication; neuropathy; thromboembolism; infection; quality of life; cost-effective]
No takes yet. Share an insight, caveat, or question.
Sive et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: